ReviewNanomedicine (London, England)2017
Cell membrane-derived nanoparticles: emerging clinical opportunities for targeted drug delivery.
Review in Nanomedicine (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Apoptotic-mimetic nanovesicles orchestrate immune-vascular-osteogenic crosstalk for critical-sized craniofacial bone regeneration.Materials today. Bio · 2026Article
- Delivery of TCM Monomers Using Blood Cell Membrane Coated Biomimetic Nanoparticles to Target CVD.International journal of nanomedicine · 2026Review
- Intranasal delivery of LB244-loaded M2 microglia membrane nanoparticles for targeted treatment of neuroinflammation after I/R brain injury.Materials today. Bio · 2025Article
- Neutrophil Membrane Nanovesicles Alleviate the Renal Function Indicators in Acute Kidney Injury Caused by Septic Rats.Cell biochemistry and biophysics · 2025Article
- Therapeutic types and advantages of functionalized nanoparticles in inducing ferroptosis in cancer therapy.Annals of medicine · 2024Review
- Review
- Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis.Journal of nanobiotechnology · 2024Article
- Navigating the nano-bio immune interface: advancements and challenges in CNS nanotherapeutics.Frontiers in immunology · 2024Review
- Shape Dependent Therapeutic Potential of Nanoparticulate System: Advance Approach for Drug Delivery.Current pharmaceutical design · 2024Review
- Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue.Redox report : communications in free radical research · 2023Article
- Programming Cell-Derived Vesicles with Enhanced Immunomodulatory Properties.Advanced healthcare materials · 2023Article
- Engineering white blood cell membrane-camouflaged nanocarriers for inflammation-related therapeutics.Bioactive materials · 2023Review
- Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.Journal of nanobiotechnology · 2023Review
- Biomimetic cell membrane-coated poly(lactic-Bioengineering & translational medicine · 2023Review
- Biomimetic semiconducting polymer dots for highly specific NIR-II fluorescence imaging of glioma.Materials today. Bio · 2022Article
- Recent progress of macrophage vesicle-based drug delivery systems.Drug delivery and translational research · 2022Review
- Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer.Advanced drug delivery reviews · 2022Review
- Cell-Inspired Biomaterials for Modulating Inflammation.Tissue engineering. Part B, Reviews · 2022Review
- "Compoundless Anaesthesia", Controlled Administration, and Post-Operative Recovery Acceleration: Musings on Theoretical Nanomedicine Applications.Journal of clinical medicine · 2022Article
- Progress and Principle of Drug Nanocrystals for Tumor Targeted Delivery.AAPS PharmSciTech · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Biofunctionalization of nanoparticles (NPs) is an essential component in targeted drug delivery. However, current nanotechnology remains inadequate to imitate complex intercellular interactions existing in physiological conditions in human bodies. Emerging concepts have been explored to utilize human cells to generate cell membrane-formed NPs because cells retain inherent abilities to interact with human tissues compared with synthetic nanomaterials. Neutrophils, red blood cells (RBCs), platelets and monocytes have been employed to form therapeutic NPs to treat vascular disease and cancer, and these novel drug delivery platforms show the translation potential to improve patient quality of life. In this review, we will discuss the concept of cell membrane-formed NPs, the molecular mechanisms of their disease targeting and the potential of personalized nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.